Flag of the European Union EU Clinical Trials Register Help

Clinical trials for myeloma AND daratumumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7272   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    92 result(s) found for: myeloma AND daratumumab. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2014-005139-14 Sponsor Protocol Number: 54767414SMM2001 Start Date*: 2015-05-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) CZ (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000752-18 Sponsor Protocol Number: 54767414MMY2002 Start Date*: 2013-11-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Pro...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-005189-31 Sponsor Protocol Number: 181114 Start Date*: 2014-12-16
    Sponsor Name:Dept Hematology SLB Vejle [...]
    1. Dept Hematology SLB Vejle
    2. Dept Hematology SLB Vejle
    Full Title: “Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”.
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028567 Myeloma, malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005709-62 Sponsor Protocol Number: GEN503 Start Date*: 2012-08-01
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open label, International, Multicenter, Dose Escalating Phase 1/2 Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Re...
    Medical condition: Relapsed or Relapsed and Refractory Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000255-85 Sponsor Protocol Number: 54767414MMY3004 Start Date*: 2014-09-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Ongoing) ES (Ongoing) CZ (Ongoing) NL (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003862-10 Sponsor Protocol Number: Dara-Atra Start Date*: 2016-04-01
    Sponsor Name:VU University Medical Center
    Full Title: A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma
    Medical condition: relapsed/refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005525-23 Sponsor Protocol Number: 54767414MMY3003 Start Date*: 2014-04-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) BE (Ongoing) NL (Completed) DK (Completed) PL (Ongoing) GR (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-003783-22 Sponsor Protocol Number: GEN501 Start Date*: 2008-12-03
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Daratumumab (HuMax-CD38) safety study in multiple myeloma – Open label, dose-escalation followed by open label, single-arm study
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002611-34 Sponsor Protocol Number: 54767414MMY2036 Start Date*: 2017-10-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects ...
    Medical condition: Relapsed or Refractory Multiple Myeloma (MM).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended) FR (Completed) GR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004349-35 Sponsor Protocol Number: 7001 Start Date*: 2021-02-02
    Sponsor Name:Klinisk Forskningsenhed, Medicinsk Afdeling, Hæmatologisk Afsnit, Sygehus Lillebælt, Vejle Sygehus
    Full Title: Melphalan flufenamide (melflufen) and Dexamethasone re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID)
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002161-36 Sponsor Protocol Number: OP-108 Start Date*: Information not available in EudraCT
    Sponsor Name:Oncopeptides AB
    Full Title: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma
    Medical condition: Patients with relapsed or relapsed-refractory multiple myeloma.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) NO (Completed) HU (Completed) FI (Completed) SK (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003253-41 Sponsor Protocol Number: PMC008 Start Date*: 2018-09-11
    Sponsor Name:Polish Myeloma Consortium
    Full Title: PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR).
    Medical condition: Multiple Myeloma and Minimal Residual Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002273-11 Sponsor Protocol Number: 54767414MMY3008 Start Date*: 2015-03-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for Hig...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) AT (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) IE (Completed) DE (Ongoing) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003554-33 Sponsor Protocol Number: 20160275 Start Date*: 2017-09-13
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Mye...
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) AT (Completed) BE (Completed) HU (Completed) BG (Completed) PL (Completed) CZ (Completed) FR (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000431-49 Sponsor Protocol Number: CC220MM002 Start Date*: 2021-10-18
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with...
    Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) NO (Ongoing) PT (Ongoing) FI (Ongoing) FR (Ongoing) SE (Ongoing) NL (Ongoing) GR (Ongoing) IE (Ongoing) BE (Ongoing) PL (Ongoing) ES (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004185-34 Sponsor Protocol Number: 54767414MMY2065 Start Date*: 2019-05-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Prematurely Ended) DK (Ongoing) NL (Prematurely Ended) FR (Ongoing) ES (Ongoing) PL (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002993-19 Sponsor Protocol Number: 54767414MMY3010 Start Date*: 2016-01-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory ...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005692-16 Sponsor Protocol Number: GEN504 Start Date*: 2012-08-01
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or ...
    Medical condition: Relapsed or Relapsed and Refractory Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001030-17 Sponsor Protocol Number: CA209-039 Start Date*: 2018-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
    Medical condition: Multiple myeloma (current protocol)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) BE (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003856-35 Sponsor Protocol Number: Uni-Koeln-3946 Start Date*: 2020-12-18
    Sponsor Name:University of Cologne
    Full Title: Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)
    Medical condition: multiple myeloma (untreated)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA